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for the three countries were used in the model. The model focused on the initial
imaging, the need for further or confirmatory imaging and unnecessary or modifi-
cation of surgery. The model will be available as an iPad application during ISPOR.
RESULTS: Using PV-MRI resulted in increased certainty in the decision-making,
demonstrated by the reduced need for further imaging: 23.5% for MD-CT, 18.5% for
ECCM-MRI and 8.6% for PV-MRI. There was a need for confirmatory imaging in
high-risk surgery patients for 7.6% and 9% in the MD-CT and ECCM-MRI groups
respectively. Unnecessary surgery was performed in 3.4% of PV-MRI and 5.4% of
MD-CT and ECCM-MTI patients respectively. The need for intra-operative modifi-
cation of the surgical plan was 7.7% for PV-MRI, 10.5% for MD-CT and 10.3% for
ECCM-MRI. The cost of imaging, unnecessary and modified surgery was €892 for
MD-CT, €997 for ECCM-MRI and €888 for PV-MRI. Additionally, it was, as expected
more patients undergoing potential curative surgery in the PV-MRI group (49.4%
versus 47.6% for MD-CT and 45.4% for ECCM-MRI). CONCLUSIONS: Using PV-MRI
rather than ECCM-MRI and MD-CT for the initial imaging in patients with CRCLM
leads to expected cost savings and reduction of unnecessary and modified surgery.
A clinical trial, using a similar protocol as the model, is currently being analyzed.
The results of the trial will be used to further validate the modeling approach and
to demonstrate the impact on health outcomes.
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inadequate management of post-operative surgical wounds can lead to delayed
healing rates and complications, notably infection. Surgical site infections (SSI)
have been shown to extend hospital stay by an average of 14 days. OPSITE POST-OP
VISIBLE (Smith & Nephew) is a surgical film dressing that provides a waterproof,
breathable, bacteria barrier for surgical wounds and allows exudate management.
The visible nature of the dressing means that the wound area can be monitored
without removal of the dressing. OBJECTIVES: to compare the costs and outcomes
associated with the use of a surgical film dressing compared to standard treatment
in the management of post-operative surgical wounds. METHODS: An economic
evaluation was conducted alongside an open controlled trial conducted in 14 cen-
tres throughout Spain which compared a surgical film dressing to the standard
treatment with gauze dressings in the management of surgical wounds; 196 pa-
tients treated with gauze and 215 with a surgical film dressing. RESULTS: SSI rates
were significantly lower in patients treated with surgical film dressing compared to
gauze dressings (6,6% vs. 1.4%, p0,006). Patients treated with the surgical film
dressing experienced fewer blisters (8,7% vs. 2,3%, p0,004), erythemas (12,2% vs.
2,8%, p0,001) and weekly dressing changes (4,81 / 2,79 vs. 1,51 /0,87,
p0,001). CONCLUSIONS: The cost of a SSI in Spain is according with evidence
published €7,966 (2010 prices). The results produce a reduction in the average cost
of treating SSI of €438 per patient when treated with the surgical film dressing. The
incremental cost of treatment with the surgical film dressing during the post-
operative period is€5. It resulted in a significant average saving, even in a partial
analysis that considered only the costs associated with treating surgical site infec-
tions. The surgical film dressing provides a simple, inexpensive solution to the
costly problem of SSI.
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OBJECTIVES:To assess the costs savings of using an implantable loop recorder (ILR)
compared to current clinical practice in the diagnosis of AF for patients who had
suffered a first cryptogenic stroke, from the perspective of a Spanish hospital.
METHODS: We calculated the hospital resource utilization in the management of
patients after a first event. Based on the ILR sensitivity to diagnose AF in order to
avoid a second event, we assumed that patients with an ILR implanted won’t suffer
a second event while patients without will. Thereafter, we calculated the resource
utilization associated to the management of the second event. All resource utiliza-
tion such as hospitalization (stroke unit and neurology department), length of stay,
pharmacological treatment, tests and others were based on expert opinion. Costs
were expressed in Euro 2012. RESULTS: The cost per patient after a fist event was
€258 for the non-ILR strategy vs. €1,838 for the ILR, basically due to the cost of
implanting the device. A second event occurring only in the non-implanted pa-
tients will cost €7,418. Finally, overall treatment costs were €1,838 for the ILR strat-
egy compared to €7,675 for the non ILR strategy. Therefore, implanting ILR will save
up to €5,838 per patient per event avoided. CONCLUSIONS: The use of the Implant-
able Loop Recorder (Reveal© XT) in patients who had already suffered a first cryp-
togenic stroke leads to an earlier diagnosis of atrial fibrillation, avoiding potential
recurrences. Preventing a second event represents a cost-saving strategy due to the
avoidance of €5,838 per patient per event; therefore, it should be included in the
clinical management of patients with a first cryptogenic stroke.
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OBJECTIVES: To examine whether rapid PCR-based screening is a cost efficient tool
to optimize pre-emptive antibiotic therapy of methicillin resistant and methicillin
sensitive S. aureusinfections. METHODS: A decision analytic cost model was devel-
oped, based on data from peer-reviewed literature. Sensitivity analyses were un-
dertaken to investigate the impact of variation in MRSA rate, cost ratio of the cost
of appropriate antibiotic therapy to cost of inappropriate antibiotic therapy, PCR
test cost and total hospital costs per case. RESULTS: At the current MSRA-rate of
24.5 % in Germany, PCR-guided treatment regimens are cost-efficient compared to
empirical strategies. Costs of alternative treatment strategies differ, on average, up
to € 1780 per case. A pre-emptive MSSA-treatment strategy with PCR test is least
costly at lower rates of MRSA, while a pre-emptive MRSA-treatment strategy with
PCR testing is the least costly approach when the MRSA rate is greater than 53.7%.
An empirical MRSA-treatment strategy is least costly when the cost ratio is less
than 1.06. When the total hospital cost per MRSA-case is increased, pre-emptive
MSSA-treatment with PCR test achieves the lowest average cost, and the cost dif-
ference between the four treatment strategies increases. CONCLUSIONS: Early
verification and adaptation of an initial pre-emptive antibiotic treatment of S. au-
reus infections using PCR-based tests are advantageous in most situations to be
expected in Germany and other European countries. PCR tests accordingly should
be considered as elements in antimicrobial stewardship programs.
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized
by uncoordinated atrial activation involving a rapid and irregular heartbeat (Fuster
et al., 2006). The prevalence of AF is1% in adults55 years old, but increases to as
much as 10% by age 80 (Go et al., 2001). The purpose of this study was to estimate
prevalence and economic burden in 2010 and forecast the prevalence and eco-
nomic burden of AF in 2015, 2020 and 2025 in selected countries. METHODS: The
prevalence and economic burden of AF in Belgium, Japan, The Netherlands, and
Spain was modeled based on prevalence rates identified via a literature search. The
prevalence and economic burden were forecasted based on 2010 estimates of AF
prevalence. Population forecasts for the selected countries were taken from United
Nations Department of Economic and Social Affairs forecasts. The adult population
was adjusted for the percentage of the population with access to health care. The
model assumed current age-adjusted prevalence rates would remain constant
through 2025. All costs are reported in 2011 euros. One-way sensitivity analysis was
performed for the health care accessible population and the country forecasted
population. RESULTS: In 2010, the prevalence and economic burden ranged from
77,700 and 236 million EUR in Belgium to 884,000 and 2.04 billion EUR in Japan. In
2025, the prevalence and economic burden ranged from 88,800 and 270 million EUR
in Belgium to 970,000 and 2.24 billion EUR in Japan. Sensitivity analyses revealed
that prevalence and economic burden were most affected by forecasted population
growth. CONCLUSIONS: The prevalence of AF in selected countries was forecasted
to grow substantially in both developing and developed countries. As the world’s
population ages and health care becomes more accessible, the economic burden of
AF will continue to rise as well.
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OBJECTIVES: Transient loss of consciousness (T-LOC) is characterised by rapid-
onset, short duration and spontaneous complete recovery. When the underlying
cause is cardiovascular, this event is known as syncope. Syncope is one of the most
common reasons for people attending the emergency department. Due to the rapid
onset of symptoms, syncope can lead to injuries and high costs. A database anal-
ysis was undertaken in five European countries to estimate the cost burden of
syncope. METHODS: Inpatient hospitalisation data were sourced from national
and local databases in France, Germany, the UK, Italy and Spain. Where possible,
the data were split according to whether syncope was the primary or secondary
diagnosis, to capture all cases in which syncope contributed to the hospitalisation.
DRG tariffs were then applied to each type of hospitalisation to estimate total costs
for each country for the period 2008-2011. RESULTS: When considering hospitali-
sations for which syncope was the primary diagnosis, annual costs per country
ranged from €90 million to €230 million (the total number of hospitalisations per
country ranged from 41,800 to 126,000). When all syncope-related hospitalisations
were considered, the annual figures per country ranged from €130 million to €305
million. In cases where syncope was a secondary diagnosis, the most common
reasons for hospitalisation were injuries to the head, pelvis and limbs. Within each
country, the results were consistent year-on-year. CONCLUSIONS: Syncope has a
significant cost burden which has been consistently observed across five major
European markets. These costs are only part of the overall burden, which also
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